Trisomie 21 et cancers

Ait Yahya-Graison, 2007, Classification of human chromosome 21 gene-expression variations in Down syndrome: impact on disease phenotypes, Am J Hum Genet, 81, 475, 10.1086/520000 Alowami, 2003, Mammographic density is related to stroma and stromal proteoglycan expression, Breast Cancer Res, 5, R129, 10.1186/bcr622 Altug-Teber, 2007, Specific transcriptional changes in human fetuses with autosomal trisomies, Cytogenet Genome Res, 119, 171, 10.1159/000112058 Baek, 2009, Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1, Nature, 459, 1126, 10.1038/nature08062 Bai, 2009, Suppression of lung cancer in murine model: treated by combination of recombinant human endostsatin adenovirus with low-dose cisplatin, J Exp Clin Cancer Res, 28, 31, 10.1186/1756-9966-28-31 Benard, 2005, Down's syndrome protects against breast cancer: is a constitutional cell microenvironment the key?, Int J Cancer, 113, 168, 10.1002/ijc.20532 Bercovich, 2008, Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome, Lancet, 372, 1484, 10.1016/S0140-6736(08)61341-0 Bierie, 2006, Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer, Nat Rev Cancer, 6, 506, 10.1038/nrc1926 Boyd, 2002, Heritability of mammographic density, a risk factor for breast cancer, N Engl J Med, 347, 886, 10.1056/NEJMoa013390 Brand-Saberi, 1994, Distribution of extracellular matrix components in nuchal skin from fetuses carrying trisomy 18 and trisomy 21, Cell Tissue Res, 277, 465, 10.1007/BF00300219 Brichard, 2003, Down syndrome: possible predisposition to retinoblastoma, Med Pediatr Oncol, 41, 73, 10.1002/mpo.10299 Busciglio, 1995, Apoptosis and increased generation of reactive oxygen species in Down's syndrome neurons in vitro, Nature, 378, 776, 10.1038/378776a0 Cabelof, 2009, Mutational spectrum at GATA1 provides insights into mutagenesis and leukemogenesis in Down syndrome, Blood, 114, 2753, 10.1182/blood-2008-11-190330 Chen, 2010, Leukaemogenesis: more than mutant genes, Nat Rev Cancer, 10, 23, 10.1038/nrc2765 Chessells, 2001, Down's syndrome and acute lymphoblastic leukaemia: clinical features and response to treatment, Arch Dis Child, 85, 321, 10.1136/adc.85.4.321 Conti, 2007, Altered expression of mitochondrial and extracellular matrix genes in the heart of human fetuses with chromosome 21 trisomy, BMC Genomics, 8, 268, 10.1186/1471-2164-8-268 Costa, 2011, Massive-scale RNA-Seq analysis of non ribosomal transcriptome in human trisomy 21, PLoS One, 6, e18493, 10.1371/journal.pone.0018493 de Haan, 2003, An altered antioxidant balance occurs in Down syndrome fetal organs: implications for the “gene-dosage effect” hypothesis, J Neural Transm Suppl, 67, 67, 10.1007/978-3-7091-6721-2_6 Delom, 2009, Transchromosomic cell model of Down syndrome shows aberrant migration, adhesion and proteome response to extracellular matrix, Proteome Sci, 7, 31, 10.1186/1477-5956-7-31 FitzPatrick, 2002, Transcriptome analysis of human autosomal trisomy, Hum Mol Genet, 11, 3249, 10.1093/hmg/11.26.3249 Fonatsch, 2010, The role of chromosome 21 in hematology and oncology, Genes Chromosomes Cancer, 49, 497 Frost, 2000, Cellular cytotoxic drug sensitivity in children with acute leukemia and Down's syndrome: an explanation to differences in clinical outcome?, Leukemia, 14, 943, 10.1038/sj.leu.2401753 Fulcher, 1998, Diabetic retinopathy in Down's syndrome, Br J Ophthalmol, 82, 407, 10.1136/bjo.82.4.407 Gittenberger-de Groot, 2003, Collagen type VI expression during cardiac development and in human fetuses with trisomy 21, Anat Rec A Discov Mol Cell Evol Biol, 275, 1109, 10.1002/ar.a.10126 Glasson, 2002, The changing survival profile of people with Down's syndrome: implications for genetic counselling, Clin Genet, 62, 390, 10.1034/j.1399-0004.2002.620506.x Grose, 2005, Fibroblast growth factor signaling in tumorigenesis, Cytokine Growth Factor Rev, 16, 179, 10.1016/j.cytogfr.2005.01.003 Gu, 2000, The PAS superfamily: sensors of environmental and developmental signals, Annu Rev Pharmacol Toxicol, 40, 519, 10.1146/annurev.pharmtox.40.1.519 Hasle, 2001, Pattern of malignant disorders in individuals with Down's syndrome, Lancet Oncol, 2, 429, 10.1016/S1470-2045(00)00435-6 Hasle, 2000, Risks of leukaemia and solid tumours in individuals with Down's syndrome, Lancet, 355, 165, 10.1016/S0140-6736(99)05264-2 Hertzberg, 2010, Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group, Blood, 115, 1006, 10.1182/blood-2009-08-235408 James, 2008, Acute leukemia in children with Down's syndrome: the importance of population-based study, Haematologica, 93, 1262, 10.3324/haematol.12831 Jemal, 2011, Global cancer statistics, CA Cancer J Clin, 61, 69, 10.3322/caac.20107 Johansson, 2009, Acute myeloid leukemia, 45 Jongewaard, 2002, Beta 1 integrin activation mediates adhesive differences between trisomy 21 and non-trisomic fibroblasts on type VI collagen, Am J Med Genet, 109, 298, 10.1002/ajmg.10413 Kearney, 2009, Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia, Blood, 113, 646, 10.1182/blood-2008-08-170928 Kim, 2011, Clinical significance of age at the time of diagnosis among young breast cancer patients, J Breast Cancer, 14, 314, 10.4048/jbc.2011.14.4.314 Korenberg, 1990, Molecular mapping of the Down syndrome phenotype, Prog Clin Biol Res, 360, 105 Korenberg, 1994, Down syndrome phenotypes: the consequences of chromosomal imbalance, Proc Natl Acad Sci U S A, 91, 4997, 10.1073/pnas.91.11.4997 Krivit, 1957, Simultaneous occurrence of mongolism and leukemia; report of a nationwide survey, AMA J Dis Child, 94, 289, 10.1001/archpedi.1957.04030040075012 Kuhn, 2008, Human chromosome 21-derived miRNAs are overexpressed in down syndrome brains and hearts, Biochem Biophys Res Commun, 370, 473, 10.1016/j.bbrc.2008.03.120 Kwak, 2007, Inhibition of breast cancer growth and invasion by single-minded 2s, Carcinogenesis, 28, 259, 10.1093/carcin/bgl122 Lee, 2006, ADAMTS1 mediates the release of antiangiogenic polypeptides from TSP1 and 2, EMBO J, 25, 5270, 10.1038/sj.emboj.7601400 Lejeune, 1959, Mongolism; a chromosomal disease (trisomy), Bull Acad Natl Med, 143, 256 Liu, 2009, Combined IFN-gamma-endostatin gene therapy and radiotherapy attenuates primary breast tumor growth and lung metastases via enhanced CTL and NK cell activation and attenuated tumor angiogenesis in a murine model, Ann Surg Oncol, 16, 1403, 10.1245/s10434-009-0343-6 Loughran, 2008, The transcription factor Erg is essential for definitive hematopoiesis and the function of adult hematopoietic stem cells, Nat Immunol, 9, 810, 10.1038/ni.1617 Loussouarn, 2008, Prognostic impact of syndecan-1 expression in invasive ductal breast carcinomas, Br J Cancer, 98, 1993, 10.1038/sj.bjc.6604400 Merrick, 2000, Incidence and mortality of Down syndrome, Isr Med Assoc J, 2, 25 Moffett, 1997, The murine Sim-2 gene product inhibits transcription by active repression and functional interference, Mol Cell Biol, 17, 4933, 10.1128/MCB.17.9.4933 Muntean, 2006, Transcription factor GATA-1 and Down syndrome leukemogenesis, Leuk Lymphoma, 47, 986, 10.1080/10428190500485810 Murdoch, 1977, Down's syndrome: an atheroma-free model?, Br Med J, 2, 226, 10.1136/bmj.2.6081.226 Ng, 2010, Trisomy of Erg is required for myeloproliferation in a mouse model of Down syndrome, Blood, 115, 3966, 10.1182/blood-2009-09-242107 Okuda, 1998, Expression of a knocked-in AML1-ETO leukemia gene inhibits the establishment of normal definitive hematopoiesis and directly generates dysplastic hematopoietic progenitors, Blood, 91, 3134, 10.1182/blood.V91.9.3134 Ou, 2007, The candidate tumor suppressor BTG3 is a transcriptional target of p53 that inhibits E2F1, EMBO J, 26, 3968, 10.1038/sj.emboj.7601825 Paszek, 2005, Tensional homeostasis and the malignant phenotype, Cancer Cell, 8, 241, 10.1016/j.ccr.2005.08.010 Patja, 2001, Cancer incidence among people with intellectual disability, J Intellect Disabil Res, 45, 300, 10.1046/j.1365-2788.2001.00322.x Patja, 2006, Cancer incidence of persons with Down syndrome in Finland: a population-based study, Int J Cancer, 118, 1769, 10.1002/ijc.21518 Patterson, 2009, Molecular genetic analysis of Down syndrome, Hum Genet, 126, 195, 10.1007/s00439-009-0696-8 Paz-Miguel, 1999, Reactive oxygen intermediates during programmed cell death induced in the thymus of the Ts(1716)65Dn mouse, a murine model for human Down's syndrome, J Immunol, 163, 5399, 10.4049/jimmunol.163.10.5399 Prandini, 2007, Natural gene-expression variation in Down syndrome modulates the outcome of gene-dosage imbalance, Am J Hum Genet, 81, 252, 10.1086/519248 Preudhomme, 2000, High incidence of biallelic point mutations in the Runt domain of the AML1/PEBP2 alpha B gene in Mo acute myeloid leukemia and in myeloid malignancies with acquired trisomy 21, Blood, 96, 2862, 10.1182/blood.V96.8.2862 Pritchard, 2008, Cytogenet Genome Res, 121, 67, 10.1159/000124384 Provenzano, 2008, Collagen density promotes mammary tumor initiation and progression, BMC Med, 6, 11, 10.1186/1741-7015-6-11 Pui, 1993, Immunophenotypes and karyotypes of leukemic cells in children with Down syndrome and acute lymphoblastic leukemia, J Clin Oncol, 11, 1361, 10.1200/JCO.1993.11.7.1361 Rabin, 2009, Malignancy in children with trisomy 21, Oncologist, 14, 164, 10.1634/theoncologist.2008-0217 Rahmani, 2006, APRO4 negatively regulates Src-tyrosine kinase activity in PC12 cells, J Cell Sci, 119, 646, 10.1242/jcs.02778 Rainis, 2005, The proto-oncogene ERG in megakaryoblastic leukemias, Cancer Res, 65, 7596, 10.1158/0008-5472.CAN-05-0147 Ravaud, 2007, The mechanism of tumor angiogenesis, Prog Urol, 17, 144 Reynolds, 2010, Tumour angiogenesis is reduced in the Tc1 mouse model of Down's syndrome, Nature, 465, 813, 10.1038/nature09106 Rozovski, 2007, Genome-wide expression analysis of cultured trophoblast with trisomy 21 karyotype, Hum Reprod, 22, 2538, 10.1093/humrep/dem214 Salek-Ardakani, 2009, ERG is a megakaryocytic oncogene, Cancer Res, 69, 4665, 10.1158/0008-5472.CAN-09-0075 Sanij, 2001, Ets-2 is induced by oxidative stress and sensitizes cells to H(2)O(2)-induced apoptosis: implications for Down's syndrome, Biochem Biophys Res Commun, 287, 1003, 10.1006/bbrc.2001.5680 Satge, 2008, Carcinogenesis in Down syndrome: what can be learned from trisomy 21?, Semin Cancer Biol, 18, 365, 10.1016/j.semcancer.2008.03.020 Satge, 2009, A medical enigma: persons with Down syndrome do not develop medulloblastoma, Neuroepidemiology, 32, 164, 10.1159/000184749 Satge, 1998, A lack of neuroblastoma in Down syndrome: a study from 11 European countries, Cancer Res, 58, 448 Satge, 2001, Breast cancer in women with trisomy 21, Bull Acad Natl Med, 185, 1239 Satge, 1998, A tumor profile in Down syndrome, Am J Med Genet, 78, 207, 10.1002/(SICI)1096-8628(19980707)78:3<207::AID-AJMG1>3.0.CO;2-M Satge, 2011, Down syndrome patients are less likely to develop some (but not all) malignant solid tumours, Clin Genet, 79, 289, 10.1111/j.1399-0004.2010.01521.x Schupf, 1997, Early menopause in women with Down's syndrome, J Intellect Disabil Res, 41, 264, 10.1111/j.1365-2788.1997.tb00706.x Seth, 2005, ETS transcription factors and their emerging roles in human cancer, Eur J Cancer, 41, 2462, 10.1016/j.ejca.2005.08.013 Sullivan, 2007, The profile and incidence of cancer in Down syndrome, J Intellect Disabil Res, 51, 228, 10.1111/j.1365-2788.2006.00862.x Sullivan, 2004, The incidence of cancer in people with intellectual disabilities, Cancer Causes Control, 15, 1021, 10.1007/s10552-004-1256-0 Sussan, 2008, Trisomy represses Apc(Min)-mediated tumours in mouse models of Down's syndrome, Nature, 451, 73, 10.1038/nature06446 Tandonnet, 2003, Myeloid leukaemia in children with Down syndrome: report of the registry-based French experience between 1990 and 2003, Pediatr Blood Cancer, 54, 927, 10.1002/pbc.22515 Taub, 1999, Expression of chromosome 21-localized genes in acute myeloid leukemia: differences between Down syndrome and non-Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin, Blood, 94, 1393 Torsdottir, 2001, Copper, ceruloplasmin and superoxide dismutase (SOD1) in patients with Down's syndrome, Pharmacol Toxicol, 89, 320, 10.1034/j.1600-0773.2001.d01-168.x van de Water, 2012, Association between age at diagnosis and disease-specific mortality among postmenopausal women with hormone receptor-positive breast cancer, JAMA, 307, 590, 10.1001/jama.2012.84 von Kaisenberg, 1998, Morphological classification of nuchal skin in human fetuses with trisomy 21, 18, and 13 at 12-18 weeks and in a trisomy 16 mouse, Anat Embryol (Berl), 197, 105, 10.1007/s004290050123 Vyas, 2007, Molecular insights into Down syndrome-associated leukemia, Curr Opin Pediatr, 19, 9, 10.1097/MOP.0b013e328013e7b2 Warkany, 1975 Wechsler, 2002, Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome, Nat Genet, 32, 148, 10.1038/ng955 Wenstrup, 2004, Type V collagen controls the initiation of collagen fibril assembly, J Biol Chem, 279, 53331, 10.1074/jbc.M409622200 Weydert, 2006, Overexpression of manganese or copper-zinc superoxide dismutase inhibits breast cancer growth, Free Radic Biol Med, 41, 226, 10.1016/j.freeradbiomed.2006.03.015 Wozniak, 2003, ROCK-generated contractility regulates breast epithelial cell differentiation in response to the physical properties of a three-dimensional collagen matrix, J Cell Biol, 163, 583, 10.1083/jcb.200305010 Xie, 2008, Extracellular matrix, Rac1 signaling, and estrogen-induced proliferation in MCF-7 breast cancer cells, Breast Cancer Res Treat, 110, 257, 10.1007/s10549-007-9719-0 Yang, 2011, Syndecan-1 in breast cancer stroma fibroblasts regulates extracellular matrix fiber organization and carcinoma cell motility, Am J Pathol, 178, 325, 10.1016/j.ajpath.2010.11.039 Yang, 2002, Mortality associated with Down's syndrome in the USA from 1983 to 1997: a population-based study, Lancet, 359, 1019, 10.1016/S0140-6736(02)08092-3 Yu, 2008, Methylation-mediated downregulation of the B-cell translocation gene 3 (BTG3) in breast cancer cells, Gene Expr, 14, 173 Zorick, 2001, High serum endostatin levels in Down syndrome: implications for improved treatment and prevention of solid tumours, Eur J Hum Genet, 9, 811, 10.1038/sj.ejhg.5200721 Zwaan, 2002, Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome, Blood, 99, 245, 10.1182/blood.V99.1.245 Zwaan, 2008, Acute leukemias in children with Down syndrome, Pediatr Clin North Am, 55, 53, 10.1016/j.pcl.2007.11.001